3. Chung JR, Kim SS, Kondor RJ, Smith C, Budd AP, Tartof SY, et al. Interim estimates of 2021–22 seasonal influenza vaccine effectiveness—United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(10):365–370. PMID:
35271561.
4. McLean HQ, Petrie JG, Hanson KE, Meece JK, Rolfes MA, Sylvester GC, et al. Interim estimates of 2022–23 seasonal influenza vaccine effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023; 72(8):201–205. PMID:
36821715.
5. Price AM, Flannery B, Talbot HK, Grijalva CG, Wernli KJ, Phillips CH, et al. Influenza vaccine effectiveness against influenza A (H3N2)-related illness in the United States during the 2021–2022 influenza season. Clin Infect Dis. 2023; 76(8):1358–1363. PMID:
36504336.
6. Domnich A, Orsi A, Ogliastro M, Trombetta CS, Scarpaleggia M, Stefanelli F, et al. Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season. Vaccine. 2023; 41(33):4861–4866. PMID:
37385889.
7. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. European IVE group. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024; 29(8):2400089. PMID:
38390651.
9. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza—the need for a universal influenza vaccine. N Engl J Med. 2018; 378(1):7–9. PMID:
29185857.
10. Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic. Vaccine. 2021; 39(8):1225–1240. PMID:
33494964.